What Does Buserelin Treat: Key Therapeutic Uses and Benefits

Buserelin is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms. The medication is relevant in contexts marked by increased discomfort or tension, and its uses generally fall into three areas: support for symptoms in hormone-dependent gynecological conditions (such as endometriosis and uterine fibroids), hormone-sensitive cancers (like advanced prostate cancer), and support for functional stability in reproductive contexts.

Buserelin is used to assist with symptom clusters that create noticeable physiological strain in these conditions. The drug is relevant for easing symptom clusters that may become intense or disruptive. When applied during phases of increased distress or discomfort, the medication contributes to easing the overall symptom load and contributes to improved day-to-day comfort.

As a general patient benefit, Buserelin supports the patient during difficult episodes by easing distress and may help maintain a sense of stability when symptoms are more noticeable. The drug is applied across conditions presenting with episodic or fluctuating manifestations, often used when symptoms intensify and supportive relief is needed.

---

Quick Fact: Support for Symptoms that interfere with daily functioning

---

Official Eligibility and Contraindication Profile

The eligibility for Buserelin is strictly defined by regulatory documents, outlining populations permitted for use, those for whom use is restricted, and those for whom it is absolutely prohibited.

Absolute Contraindications (Must Not Use)

Classification	Prohibited Population	Regulatory Basis
Hypersensitivity	Patients with known allergy to Buserelin, other LHRH agonists, or product excipients.	Explicit Labeling
Pregnancy/Lactation	Women who are pregnant, may become pregnant, or are breastfeeding.	Risk of Fetal Harm
Other	Women with undiagnosed abnormal vaginal bleeding. Men with non-hormone-dependent prostate cancer or who have undergone orchiectomy.	Explicit Labeling

Conditional Use and Restrictions

Age and Excipient Restrictions

The injection formulation is contraindicated in newborns and premature infants due to the presence of the excipient benzyl alcohol. For primary adult indications, use is generally not established for children under 18 years of age.

Comorbidity-Based Restrictions

Use requires special caution and close monitoring in patients with pre-existing conditions, including diabetes mellitus (risk of impaired glucose control), hypertension, a history of cardiovascular disease (e.g., heart attack, stroke), and a history of depression (risk of worsening symptoms). Patients with risk factors for osteoporosis or severe liver/kidney disease also require caution.

---

Connection to the overall eligibility profile

Official regulatory documents strictly define who can and cannot use Buserelin by establishing non-negotiable absolute contraindications (such as pregnancy and hypersensitivity) and by mandating conditions for restricted use in patients with certain chronic comorbidities. This structure ensures adherence to established safety margins, with the final eligibility decision remaining exclusively guided by these governmental label-based rules.

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Buserelin Acetate, primarily focused on pharmacodynamic effects and the sequencing of administration.

Documented Interaction Patterns

Interaction Type	Interacting Agents / Conditions	Regulatory Requirement
Additive Cardiac Risk	QT-prolonging medicinal products (e.g., quinidine, sotalol, amiodarone, methadone)	Co-administration may increase the risk or severity of heart rhythm problems (QTc prolongation).
Contraindicated Condition	Congenital long QT syndrome	Buserelin implant formulation must not be administered; mandatory discontinuation if QT prolongation develops during treatment.
Efficacy Interference	Antidiabetic agents (e.g., Acarbose, Alogliptin)	Co-administration may decrease the therapeutic efficacy of the antidiabetic agent.

Administration and Monitoring Constraints

Specific timing rules apply in certain contexts. For infertility protocols, Buserelin administration must be stopped before the subsequent administration of hormones used to stimulate ovulation. For patients with pre-existing conditions, the official profile notes the requirement for close monitoring of blood glucose levels for those with diabetes and blood pressure for those with hypertension, due to the drug’s potential impact on these metrics.

Furthermore, chronic alcohol abuse and smoking are cited in regulatory documents as co-existing factors that pose an additional risk of bone mineral content changes during LHRH agonist therapy.

How Buserelin Works

Buserelin is a synthetic peptide that targets the Gonadotropin-Releasing Hormone (GnRH) receptors located on the gonadotroph cells in the anterior pituitary gland. Its mechanism is defined by a necessary biphasic action. As an agonist, it initially binds strongly, causing a transient surge, or "flare," in the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).

However, this continuous, non-pulsatile stimulation rapidly leads to receptor desensitization and downregulation. The GnRH receptors are internalized, forcing the pituitary into a functionally refractory state. This key mechanistic cascade results in the profound disruption of the Hypothalamic-Pituitary-Gonadal (HPG) axis.

By suppressing the secretion of LH and FSH, Buserelin removes the essential trophic signals required by the sex organs. This lack of stimulation leads directly to a deep, reversible suppression of circulating Testosterone and Estradiol levels, defining the molecule's core physiological action.

How to Use Бусерелин: Official Administration Guidelines

Buserelin is administered through distinct routes and schedules, which are standardized across its official uses.

---

Administration Routes and Standard Dosing

Buserelin is available for Subcutaneous (SC) injection, Intranasal (nasal spray), and Subcutaneous Implant (depot). The dosage form dictates the regimen:

Administration Route	Indication / Phase	Standard Dosing Regimen	Frequency / Duration
SC Injection	Initial Phase (Prostatic Carcinoma)	500 mu g	Three times daily for 7 days
SC Injection	Maintenance (Prostatic Carcinoma)	200 mu g	Once daily
Nasal Spray	Maintenance (Carcinoma/Endometriosis)	400 mu g	Three times daily
SC Implant	Long-Term (Prostatic Carcinoma)	6.3 mg or 9.45 mg	Every 2 or 3 months

For assisted reproductive technology (ART) protocols, the SC injection dose typically ranges from 200 to 500 mu g daily and continues until pituitary down-regulation is achieved.

---

Key Procedural Requirements

• Co-Treatment: For the treatment of prostatic carcinoma, an anti-androgen is officially recommended to begin approximately 5 days before the first Buserelin dose and is continued for the initial 3 to 4 weeks of therapy.
• Administration: The SC implant must be administered by a healthcare professional into the abdominal wall, maintaining a regular 2- or 3-month interval. For SC injections, site rotation is specified to minimize local reactions. For the nasal spray, clearing the nasal passages prior to use is instructed to ensure proper absorption.
• Duration: Therapy for benign gynecological conditions, such as endometriosis, is typically limited to 6 months and should not exceed 9 months.

Research Evidence / Overview of Studies for Бусерелин

---

Evidence for Use in Advanced Prostate Cancer

The evidence base for Buserelin in advanced prostate cancer was evaluated in long-term Randomized Controlled Trials (RCTs) and systematic reviews that included other established treatments as comparators. A central focus of research in these studies was to explore Overall Survival (OS) and Progression-Free Survival (PFS) in men with advanced disease. Researchers also actively monitored the achievement and maintenance of Castrate-Level Testosterone Suppression, which serves as a key biomarker endpoint tracked by researchers.

Studies monitored patient groups who reported achieving and maintaining hormone suppression levels that were within the expected range for the GnRH agonist class. Research tracked patterns in how patients reported their daily functioning throughout the trial duration. The body of evidence often aggregates results for Buserelin with data from other GnRH agonists, meaning reports on the specific, distinct outcomes of Buserelin alone are limited in many large systematic reviews.

---

Evidence for Hormone-Dependent Gynecological Conditions (Endometriosis and Uterine Fibroids)

The research landscape for Buserelin in conditions like endometriosis and uterine fibroids was evaluated in short-term, controlled clinical trials. These studies were studied for changes in patient-reported symptoms, particularly outcomes related to physical discomfort such as pelvic pain. Researchers also examined whether Buserelin treatment was associated with a measurable change in the size of lesions or fibroids.

Studies examined symptom scores that were reported during the active treatment phase, typically limited to about six months. The research examined changes measured in estradiol levels, which were tracked as part of the primary outcome axis. However, reports from various observational follow-up studies indicated patterns of symptom recurrence in some patients after the short active treatment period was concluded. Long-term outcomes are not fully established beyond the initial six months of treatment, and data for certain patient groups remain insufficient.

Common questions about Бусерелин (FAQ)

Q: What is Бусерелин (Buserelin) and what is it used for?

Buserelin is a synthetic analogue of gonadotropin-releasing hormone (GnRH), also known as Luteinizing Hormone-Releasing Hormone (LHRH). It is a highly potent medicine that initially stimulates the release of pituitary hormones, but with continued use, it leads to a reversible suppression of hormone release.

It is used to treat hormone-dependent conditions in both men and women, including:

• Prostate cancer in men.
• Endometriosis, uterine fibroids (leiomyoma), and infertility treatment (as part of controlled ovarian stimulation) in women.

Q: How does Buserelin work?

Buserelin works by binding to receptors in the pituitary gland. When treatment begins, it causes a brief, initial surge in the production of sex hormones (testosterone in men, estrogen in women). This is often called a 'flare' effect.

However, with continuous daily administration, Buserelin causes the pituitary gland's receptors to become desensitized (down-regulated). This significantly reduces the amount of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) released. The resulting drop in LH and FSH leads to a dramatic reduction in the production of sex hormones by the ovaries and testes, which is the desired therapeutic effect for treating hormone-sensitive conditions.

Q: What are the main forms of Buserelin (Buserelin Acetate) available?

Buserelin is primarily available in two main forms, which dictate the dosing schedule and method of administration:

1. Injectable Solution (Nasal Spray or Subcutaneous Injection): This form requires daily administration to maintain the continuous suppression effect. It is often used for conditions where a short-term, reversible suppression is needed, such as in preparation for in vitro fertilization (IVF) protocols.
2. Depot Formulations (Injectable Microcapsules or Implants): These are long-acting injections given less frequently, typically every 4 weeks. The depot slowly releases the medication over time, which is essential for sustained suppression needed in the treatment of long-term conditions like prostate cancer or endometriosis.

Q: What are the common side effects of Buserelin?

Side effects are often related to the temporary increase in sex hormones at the start of treatment (the flare-up) or the sustained decrease in sex hormones later on (chemical castration effect).

Common side effects include:

• In Women: Hot flashes, sweating, changes in mood or emotional state, headaches, and vaginal dryness.
• In Men: Hot flashes, sweating, decreased libido (sex drive), erectile dysfunction, and breast swelling or tenderness (gynecomastia).
• General: Fatigue, injection site reactions (for depot forms), and general discomfort.

It is important to discuss all potential side effects and any concerning symptoms with a healthcare professional.

How to Store and Dispose of Buserelin

Official regulatory guidelines define specific conditions for Buserelin's storage, handling, and disposal.

Storage and Stability

Condition	Requirement (Official Labeling)
Temperature	Store typically below 25 C (room temperature) or refrigerated (2 C to 8 C), depending on the formulation. Do not freeze.
Protection	Store in the original container and outer carton to protect the medication from light.
In-Use Stability	Multidose vials must be discarded 15 days (or 2 weeks) after first use; nasal sprays must be discarded 5 weeks after first opening.

Handling and Disposal

Buserelin must be kept out of the reach of children and pets at all times. Use aseptic technique when handling the injection. Avoid contact with skin and eyes.

Disposal should be managed through designated community drug take-back programs, which are the preferred option. If a program is unavailable, unused or expired medication should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed bag before being thrown in the household trash. Needles and other sharps must be disposed of in an approved sharps container; never reuse them.